| Cat. No. |
Product Name & Pharmacological Action |
| 1701 | A 77636 hydrochloride |
| Potent, selective D1-like agonist. Orally active |
| 1702 | N6-Cyclopentyladenosine |
| Potent, selective A1 agonist |
| 1704 | Ionomycin calcium salt |
| Calcium ionophore |
| 1705 | 2-Chloro-N6-cyclopentyladenosine |
| Potent, selective A1 agonist |
| 1706 | Acetaminophen |
| Cyclooxygenase inhibitor; may be selective for COX-3 |
| 1707 | Sulindac |
| Cyclooxygenase inhibitor (following metabolism to sulindac sulfide) |
| 1708 | Indomethacin |
| Cyclooxygenase inhibitor (COX-1 > COX-2) |
| 1709 | CL 218872 |
| Benzodiazepine agonist |
| 1710 | CV 1808 |
| Adenosine A2 receptor agonist |
| 1711 | TocriscreenTM Complete Collection |
| Compound library |
| 1712 | TocriscreenTM Neuroscience Collection |
| Compound library |
| 1713 | TocriscreenTM Signal Transduction Collection |
| Compound library |
| 1714 | TocriscreenTM Adenosines |
| Collection of adenosine receptor and related compounds |
| 1715 | TocriscreenTM Adrenergics |
| Collection of adrenoceptor and related compounds |
| 1716 | TocriscreenTM Cannabinoids |
| Collection of cannabinoid receptor and related compounds |
| 1717 | TocriscreenTM Cholinergics |
| Collection of cholinergic receptor and related compounds |
| 1718 | TocriscreenTM Dopaminergics |
| Collection of dopamine receptor and related compounds |
| 1719 | TocriscreenTM Enzyme Inhibitors |
| Collection of enzyme inhibitors |
| 1720 | TocriscreenTM GABA/Glycine Ligands |
| Collection of GABA/glycine receptor and related compounds |
| 1721 | TocriscreenTM Glutamate Ligands |
| Collection of glutamate receptor and related compounds |
| 1722 | TocriscreenTM Histaminergics |
| Collection of histamine receptor and related compounds |
| 1723 | TocriscreenTM Imidazolines |
| Collection of imidazoline receptor and related compounds |
| 1724 | TocriscreenTM Ion Channel Modulators |
| Collection of ion channel modulators |
| 1725 | TocriscreenTM Melatonergics |
| Collection of melatonin receptor and related compounds |
| 1726 | TocriscreenTM Nitric Oxide |
| Collection of nitric oxide tools |
| 1727 | TocriscreenTM Opioids |
| Collection of opioid receptor and related compounds |
| 1728 | TocriscreenTM Peptide Receptor Ligands |
| Collection of peptide receptor and related compounds |
| 1729 | TocriscreenTM Prostanoids |
| Collection of prostanoid receptor and related tools |
| 1730 | TocriscreenTM Purinergics |
| Collection of purinergic receptor and related compounds |
| 1731 | TocriscreenTM Retinoids and PPARs |
| Collection of retinoid and PPAR receptor and related tools |
| 1732 | TocriscreenTM Serotonergics |
| Collection of 5-HT receptor and related compounds |
| 1733 | TocriscreenTM Sigma Ligands |
| Collection of sigma receptor and related compounds |
| 1734 | TocriscreenTM Calcium Signalling |
| Collection of calcium signalling tools |
| 1735 | TocriscreenTM Cyclic Nucleotide Tools |
| Collection of cyclic nucleotide tools |
| 1736 | TocriscreenTM Lipid Signalling |
| Collection of lipid signalling tools |
| 1737 | TocriscreenTM Protein Kinase/Phosphatase Tools |
| Collection of protein kinase/protein phosphatase tools |
| 1738 | TocriscreenTM Cell Cycle and Apoptosis |
| Collection of cell cycle and apoptosis tools |
| 1739 | TocriscreenTM Steroid Hormones |
| Collection of steroid hormone receptor and related tools |
| 1740 | TocriscreenTM Vanilloids |
| Collection of vanilloid receptor and related tools |
| 1741 | TocriscreenTM Miscellaneous Signalling |
| Collection of miscellaneous signalling tools |
| 1742 | R-96544 hydrochloride |
| Potent, selective 5-HT2A antagonist |
| 1743 | Bay 11-7085 |
| Irreversible inhibitor of TNF-α-induced IκBα phosphorylation |
| 1744 | Bay 11-7821 |
| Irreversible inhibitor of TNF-α-induced IκBα phosphorylation |
| 1746 | Nemonapride |
| Highly potent D2-like antagonist. Also 5-HT1A agonist |
| 1747 | Isoproterenol hydrochloride |
| Standard selective β-adrenoceptor agonist |
| 1748 | MG 132 |
| Proteasome and calpain inhibitor. Inhibits NF-κB activation |
| 1749 | HexylHIBO |
| Group I mGlu antagonist |
| 1750 | (S)-HexylHIBO |
| Group I mGlu antagonist |
| 1757 | ALX 5407 hydrochloride |
| Selective non-transportable GlyT1 inhibitor |
| 1758 | PETCM |
| Activator of caspase-3 |
| 1759 | Nilutamide |
| Androgen receptor antagonist. Orally active |
| 1760 | (±)-Blebbistatin |
| Selective inhibitor of myosin II |
| 1761 | Baicalein |
| 5- and 12-Lipoxygenase inhibitor |
| 1762 | Acifran |
| Hypolipidaemic agent; agonist for the GPR109a (HM74A) and GPR109b receptors |
| 1763 | BAM (8-22) |
| Selective agonist for the sensory neuron specific receptor (SNSR) |
| 1764 | Hemopressin |
| Bioactive substrate for endopeptidase 24.15, neurolysin and ACE |
| 1765 | UBP 282 |
| AMPA/kainate antagonist; distinguishes between motoneuron and dorsal root kainate receptors |
| 1766 | UBP 301 |
| Kainate receptor antagonist |
| 1767 | Zimelidine dihydrochloride |
| Selective 5-HT uptake inhibitor |
| 1768 | Fumagillin |
| Methionine aminopeptidase-2 inhibitor |
| 1769 | Flurbiprofen |
| Cyclooxygenase inhibitor |
| 1770 | Deguelin |
| Anticancer and antiviral agent; chemopreventive and proapoptotic |
| 1771 | S 14506 hydrochloride |
| Highly potent 5-HT1A agonist; displays unique binding mechanism |
| 1772 | Urapidil hydrochloride |
| α1 antagonist. Also 5-HT1A receptor agonist |
| 1774 | Dynamin inhibitory peptide |
| Dynamin inhibitor |
| 1775 | Dynamin inhibitory peptide, myristoylated |
| Cell-permeable dynamin inhibitor |
| 1776 | Dynamin inhibitory peptide, myristoylated (control) |
| Control peptide version of Cat. Nos. 1774 and 1775 |
| 1777 | Arctigenin |
| Inhibitor of IκBα phosphorylation. Also inhibits MKK1 |
| 1778 | Ro 106-9920 |
| Inhibitor of NF-κB activation |
| 1779 | NNC 711 |
| Selective inhibitor of GAT-1 |
| 1780 | NNC 63-0532 |
| Potent non-peptide ORL1 agonist; brain penetrant |
| 1781 | ACPA (in TocrisolveTM 100) |
| Potent, selective CB1 agonist (in water-soluble emulsion) |
| 1782 | (R)-(+)-Methanandamide (in TocrisolveTM 100) |
| Potent and selective CB1 agonist (in water-soluble emulsion) |
| 1783 | JWH 133 (in TocrisolveTM 100) |
| Potent, selective CB2 agonist (in water-soluble emulsion) |
| 1784 | Spantide I |
| Selective NK1 antagonist |
| 1785 | Bax inhibitor peptide V5 |
| Inhibitor of Bax-mediated apoptosis |
| 1786 | Bax inhibitor peptide P5 |
| Inhibitor of Bax-mediated apoptosis |
| 1787 | Bax inhibitor peptide, negative control |
| Negative control peptide for Cat. Nos. 1785 and 1786 |
| 1788 | GRP (porcine) |
| Endogenous GRP receptor agonist |
| 1789 | GRP (human) |
| Endogenous GRP receptor agonist |
| 1790 | Pseudo RACK1 |
| Protein kinase C activator peptide (attached to cell permeable vector) |
| 1791 | PKC z pseudosubstrate |
| PKC z inhibitor peptide (attached to cell-permeable vector) |
| 1792 | PKC β pseudosubstrate |
| Selective cell-permeable PKC inhibitor peptide (attached to vector) |
| 1793 | AF 12198 |
| Potent, selective human type I IL-1 receptor antagonist |
| 1794 | Ro 26-4550 trifluoroacetate |
| Competitive inhibitor of IL-2/ IL-2Rα receptor interaction |
| 1795 | Zacopride hydrochloride |
| Highly potent 5-HT3 receptor antagonist. Also 5-HT4 agonist |
| 1797 | OMDM-2 |
| Potent inhibitor of anandamide uptake |
| 1798 | Gabexate mesylate |
| Serine proteinase inhibitor; inhibits thrombin, trypsin, kallikrein and plasmin |
| 1799 | WKYMVM |
| Selective FPRL1 and FPRL2 receptor agonist |
| 1800 | WKYMVm |
| FPR, FPRL1 and FPRL2 receptor agonist |
| |